$363 Million is the total value of Avoro Capital Advisors LLC's 31 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACAD | New | ACADIA PHARMACEUTICALS INC | $20,731,000 | – | 495,000 | +100.0% | 5.71% | – |
| VNDA | New | VANDA PHARMACEUTICALS INC | $18,257,000 | – | 1,438,693 | +100.0% | 5.03% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC | $8,886,000 | – | 352,350 | +100.0% | 2.45% | – |
| VCYT | New | VERACYTE INC | $8,450,000 | – | 758,497 | +100.0% | 2.33% | – |
| AXGT | New | AXOVANT SCIENCES LTD. | $6,929,000 | – | 340,000 | +100.0% | 1.91% | – |
| New | NEURODERM LTD. | $5,697,000 | – | 371,111 | +100.0% | 1.57% | – | |
| HRTX | New | HERON THERAPEUTICS INC | $4,674,000 | – | 150,000 | +100.0% | 1.29% | – |
| ALQA | New | ALLIQUA BIOMEDICAL INC | $4,216,000 | – | 800,000 | +100.0% | 1.16% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS-ADRsponsored adr | $3,371,000 | – | 183,900 | +100.0% | 0.93% | – |
| FBIO | New | FORTRESS BIOTECH INC. | $3,123,000 | – | 929,531 | +100.0% | 0.86% | – |
| BIIB | New | BIOGEN INC | $1,818,000 | – | 4,500 | +100.0% | 0.50% | – |
| New | SPDR SERIES TRUST - S&P BIOTECHput | $770,000 | – | 350,000 | +100.0% | 0.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.